Breakthrough in cancer treatment
Wednesday 16 April 1997
In one of the first trials of a genetically engineered vaccine, a team at the Johns Hopkins Oncology Centre in Baltimore, Maryland, succeeded in activating patients' immune systems.
The vaccine was given to 18 patients with advanced kidney cancer to test its safety and effectiveness over an eight-year period. One patient, whose tumour continued to grow and spread to his lungs after surgery, showed a substantial improvement for several months after receiving the vaccine.
Although the rest showed no signs of remission, all had measurable immune responses. Many patients died within the first year of the trial.
The findings are reported in the journal Cancer Research.
- 1 'Sickening, deluded and unforgivable': Bloody attack brings terror to capital’s streets
- 2 Mothers' diets may harm IQs in two-thirds of babies
- 3 Gay couple beaten in park urge MPs to moderate language on gay marriage
- 4 After woman sells virginity for $780,000, here are the results of our prostitution survey
- 5 Far-right French historian, 78-year-old Dominique Venner, commits suicide in Notre Dame in protest against gay marriage
BMF is the UK’s biggest and best loved outdoor fitness classes
Find out what The Independent's resident travel expert has to say about one of the most beautiful small cities in the world
Win anything from gadgets to five-star holidays on our competitions and offers page.